Furthermore, the synergistic effect of SGLT-2 inhibitors and doxorubicin, as demonstrated in breast cancer cells, makes it conceivable that this synergism with SGLT-2 inhibitors will also be confirmed in other tumour types and with other classic anticancer drugs. The gene discussed is SLC5A2; the disease is breast carcinoma.